Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Hospital of University of Pennsylvania, Philadelphia, Pennsylvania University of Pennsylvania Center for Human Phenomic Science (CHPS), Philadelphia, Pennsylvania